- Home
- FSBC vs PHAR Comparison
FSBC vs PHAR Comparison
Compare FSBC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSBC
- PHAR
- Stock Information
- Founded
- FSBC 2002
- PHAR 1988
- Country
- FSBC United States
- PHAR Netherlands
- Employees
- FSBC N/A
- PHAR N/A
- Industry
- FSBC Banks
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- FSBC Finance
- PHAR Health Care
- Exchange
- FSBC Nasdaq
- PHAR Nasdaq
- Market Cap
- FSBC 628.9M
- PHAR 1.0B
- IPO Year
- FSBC 2021
- PHAR N/A
- Fundamental
- Price
- FSBC $32.82
- PHAR $14.68
- Analyst Decision
- FSBC Buy
- PHAR Strong Buy
- Analyst Count
- FSBC 5
- PHAR 3
- Target Price
- FSBC $34.80
- PHAR $30.00
- AVG Volume (30 Days)
- FSBC 29.3K
- PHAR 11.4K
- Earning Date
- FSBC 10-27-2025
- PHAR 10-23-2025
- Dividend Yield
- FSBC 2.44%
- PHAR N/A
- EPS Growth
- FSBC 2.40
- PHAR N/A
- EPS
- FSBC 2.44
- PHAR N/A
- Revenue
- FSBC $132,133,000.00
- PHAR $339,836,000.00
- Revenue This Year
- FSBC $33.14
- PHAR $16.63
- Revenue Next Year
- FSBC $15.40
- PHAR $6.77
- P/E Ratio
- FSBC $13.46
- PHAR N/A
- Revenue Growth
- FSBC 18.01
- PHAR 22.44
- 52 Week Low
- FSBC $22.22
- PHAR $7.10
- 52 Week High
- FSBC $35.13
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- FSBC 59.94
- PHAR 57.93
- Support Level
- FSBC $32.20
- PHAR $13.51
- Resistance Level
- FSBC $33.33
- PHAR $15.61
- Average True Range (ATR)
- FSBC 0.77
- PHAR 0.90
- MACD
- FSBC -0.06
- PHAR -0.05
- Stochastic Oscillator
- FSBC 68.52
- PHAR 62.58
About FSBC Five Star Bancorp
Five Star Bancorp is a bank holding company through its subsidiary it operates in California state-chartered non-member bank. The Company provides a broad range of banking products and services to small and medium-sized businesses, professionals, and individuals. It offers loan products like commercial real estate loans, commercial loans, commercial land and construction loans, and farmland loans and offers deposit products like checking accounts, savings accounts, money market accounts, and term certificate accounts. The group has one reportable operating segment; Banking.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.